MEDIA INQUIRIES
Bernadette Cupit (908) 334-4554
bcupit@omeza.com
Case Studies of Patients with Diabetic Foot Ulcers Showed 90 to 100 Percent Wound Closure at 12 weeks Following Weekly Treatment with Novel OMEZA® OCM™
–Three case studies reinforce clinical trial data demonstrating dramatic healing rates among patients with diabetic foot ulcers treated with OCM™ – CLEVELAND – June 11, 2024 – Omeza®, a regenerative skincare company …
OMEZA® CLINICAL STUDY TO EVALUATE OCM™ WOUND MATRIX FOR THE TREATMENT OF CHRONIC CUTANEOUS WOUNDS/ULCERS OF MULTIPLE ETIOLOGIES HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS WILL BE SUBMITTED TO A PEER REVIEW JOURNAL.
Sarasota, FL June 6, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced completion of a multi-center clinical study which evaluated …
NOVEL OMEZA® OCM™ WOUND MATRIX CLINICAL STUDY IN VENOUS LEG ULCERS HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS TO BE SUBMITTED TO PEER REVIEW JOURNAL
Sarasota, FL June 5, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced completion of a multi-center open label study comparing …
POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCM™ AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PSEUDOMONAS AERUGINOSA (PA) IN PORCINE WOUND MODEL
Sarasota, Fla, May 20, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, recently presented in vivo data showing that OCM™ wound matrix alone …
